A detailed history of Quantbot Technologies LP transactions in Xencor Inc stock. As of the latest transaction made, Quantbot Technologies LP holds 269 shares of XNCR stock, worth $4,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares
269
Holding current value
$4,917
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$15.7 - $21.65 $4,223 - $5,823
269 New
269 $5,000
Q1 2024

May 06, 2024

SELL
$18.65 - $26.52 $207,014 - $294,372
-11,100 Reduced 76.55%
3,400 $75,000
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $239,685 - $310,590
14,500 New
14,500 $307,000
Q2 2023

Aug 08, 2023

BUY
$24.77 - $29.9 $79,264 - $95,680
3,200 New
3,200 $79,000
Q3 2021

Nov 09, 2021

SELL
$30.65 - $35.68 $30,833 - $35,894
-1,006 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$34.33 - $44.68 $21,593 - $28,103
629 Added 166.84%
1,006 $34,000
Q1 2021

May 14, 2021

BUY
$40.81 - $53.88 $15,385 - $20,312
377 New
377 $16,000
Q2 2020

Aug 13, 2020

SELL
$27.76 - $33.42 $21,069 - $25,365
-759 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$20.69 - $37.79 $41,297 - $75,428
-1,996 Reduced 72.45%
759 $22,000
Q4 2019

Feb 10, 2020

BUY
$32.75 - $41.43 $47,422 - $59,990
1,448 Added 110.79%
2,755 $94,000
Q3 2019

Nov 12, 2019

BUY
$33.73 - $46.27 $44,085 - $60,474
1,307 New
1,307 $44,000
Q4 2018

Feb 13, 2019

SELL
$32.39 - $42.05 $7,255 - $9,419
-224 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$35.69 - $47.65 $71,736 - $95,776
-2,010 Reduced 89.97%
224 $8,000
Q2 2018

Aug 13, 2018

SELL
$28.41 - $42.41 $27,358 - $40,840
-963 Reduced 30.12%
2,234 $82,000
Q1 2018

May 11, 2018

BUY
$21.18 - $33.78 $67,712 - $107,994
3,197 New
3,197 $95,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.09B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.